Explore the words cloud of the Respiratory-ImmunoDx project. It provides you a very rough idea of what is the project "Respiratory-ImmunoDx" about.
The following table provides information about the project.
MEMED DIAGNOSTICS LTD
|Coordinator Country||Israel [IL]|
|Total cost||2˙935˙000 €|
|EC max contribution||2˙935˙000 € (100%)|
1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
2. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2015-12-01 to 2018-11-30|
Take a look of project's partnership.
|1||MEMED DIAGNOSTICS LTD||IL (TIRAT CARMEL)||coordinator||2˙935˙000.00|
Lower respiratory tract infection (LRTI) is the 3rd leading cause of death worldwide. In the EU 30 million incidents occur annually, with associated costs of €46 billion. Older adults are at higher risk of developing LRTI, and therefore, in light of Europe's ageing population, the disease burden will increase. Since most adult LRTIs are managed in the outpatient setting, innovative diagnostic tools for guiding treatment at the point-of-need (PON), would be impactful. MeMed identified a host-biomarker signature comprising a novel viral induced protein called TRAIL. Based on this signature, MeMed developed a test called ImmunoXpertTM (CE-IVD approved). In a prospective study with >1000 patients, ImmunoXpert™ accurately distinguished viral versus bacterial infections, significantly outperforming traditional tests. Two factors prohibit wide adoption of ImmunoXpert for managing LRTI adult patients: i) insufficient clinical evidence validating the signature in this subpopulation and ii) ImmunoXpert™ is performed in a lab and requires 2 hours. To address this we propose:
• To clinically validate the biomarker signature for accurate diagnosis of viral versus bacterial LRTI, in a prospective study enrolling 1100 adult EU patients at the PON
• To develop, validate and obtain EU regulatory clearance for a new PON device (to be called ImmunoDx™) that rapidly measures the signature from a drop of blood
These objectives are highly aligned with the SME instrument goals and MeMed’s strategy. They will allow a pioneering test to achieve accelerated market adoption, initially in Europe and then globally. The validated signature, measured using ImmunoDx™, will give physicians, accurate and actionable information at the PON. This test has potential to profoundly impact patients' quality of life by reducing adverse effects due to antibiotic overuse; reducing complications and mortality due to underuse; and slowing the emergence of antibiotic resistant bacteria, a major public health
|A dedicated website for OBSERVER and ImmunoDxâ„¢||Websites, patent fillings, videos etc.||2019-05-31 17:19:04|
|Presenting at infectious disease conference||Websites, patent fillings, videos etc.||2019-05-31 17:19:02|
Take a look to the deliverables list in detail: detailed list of Respiratory-ImmunoDx deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESPIRATORY-IMMUNODX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RESPIRATORY-IMMUNODX" are provided by the European Opendata Portal: CORDIS opendata.
Clinical validation of host biomarker signature for distinguishing bacterial versus viral lower respiratory tract infections (LRTI) in adults at the point-of-needRead More
Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease.Read More